Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC

25 Jun 2014

Abstract excerpt

The RAS/RAF/MEK/ ERK and the PI3K/AKT/mTOR pathways govern fundamental physiological processes, such as cell proliferation, differentiation, metabolism, cytoskeleton reorganization and cell death and survival. Constitutive activation of these signal transduction pathways is a required hallmark of cancer and dysregulation, on either genetic or epigenetic grounds, of these pathways has been implicated in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Treatment and Pharmacology
Share to PI3K/AKT/mTOR signaling in cancer
Share to Synthesis and biological activity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24138714
DOI: 10.2174/13816128113196660763

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLCPMID 24138714Read ↗

Unraveling the prevalence of various signalling pathways in non-small-cell lung cancer: a review.Semantic proximity Read ↗

Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC.Semantic proximity Read ↗

New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.Semantic proximity Read ↗

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.Semantic proximity Read ↗

In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC.Semantic proximity Read ↗

BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it.Semantic proximity Read ↗

Key signaling pathways in thyroid cancerSemantic proximity Read ↗

A Comprehensive Review on MAPK: A Promising Therapeutic Target in CancerSemantic proximity Read ↗

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancerSemantic proximity Read ↗

Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways.Semantic proximity Read ↗

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapySemantic proximity Read ↗

Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.